European Journal of Heart Failure, Journal Year: 2023, Volume and Issue: 25(11), P. 1887 - 1890
Published: Nov. 1, 2023
Language: Английский
ESC Heart Failure, Journal Year: 2024, Volume and Issue: unknown
Published: May 28, 2024
Abstract In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of 2021 HF guidelines introduced new key recommendations based on results years science. First, two drugs, sodium–glucose co‐transporter‐2 (SGLT2) inhibitors and finerenone, a novel nonsteroidal, selective mineralocorticoid receptor antagonist (MRA), are recommended for prevention patients with diabetic chronic kidney disease (CKD). Second, SGLT2 now treatment across entire left ventricular ejection fraction spectrum. benefits quadruple therapy reduced (HFrEF) well established. Its rapid early up‐titration along close follow‐up frequent clinical laboratory re‐assessment after an episode acute (the so‐called ‘high‐intensity care’ strategy) was associated better outcomes STRONG‐HF trial. Patients experiencing worsening might require fifth drug, vericiguat. STEP‐HFpEF‐DM STEP‐HFpEF trials, semaglutide 2.4 mg once weekly administered 1 year decreased body weight significantly improved quality life 6 min walk distance obese preserved (HFpEF) or without history diabetes. Further data safety efficacy, including also hard endpoints, needed to support addition acetazolamide hydrochlorothiazide standard diuretic regimen hospitalized due HF. meantime, PUSH‐AHF supported use natriuresis‐guided therapy. options most recent evidence HF, specific drugs cardiomyopathies (i.e., mavacamten hypertrophic cardiomyopathy tafamidis transthyretin cardiac amyloidosis), device therapies, contractility modulation percutaneous valvulopathies, finding from TRILUMINATE Pivotal trial, reviewed this article.
Language: Английский
Citations
31
European Journal of Heart Failure, Journal Year: 2023, Volume and Issue: 26(2), P. 327 - 337
Published: Nov. 7, 2023
Persistent symptoms despite guideline-directed medical therapy (GDMT) and poor tolerance of GDMT are hallmarks patients with advanced heart failure (HF) reduced ejection fraction (HFrEF). However, real-world data on use, dose, prognostic implications lacking.
Language: Английский
Citations
24
Journal of Cardiac Failure, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
During the last century characteristics of patients with heart failure (HF) and acute HF (AHF) have shifted from severe pump due to rheumatic, hypertensive ischemic disease older more obese multiple comorbidities. The pathophysiology AHF has in parallel that advanced, end-stage, caused by left ventricular dysfunction age, obesity comorbidity-related cardiovascular combined neurohormonal inflammatory dysregulation or "inflammaging". With advent blockers leading improved outcomes chronic HF, focus therapy also changed care directed at early symptom improvement therapies towards longer-term improvements quality life outcomes. Studies conducted 5 years suggest beneficial effects seen 4 pillars guideline-directed medical for mostly comprising blockade, can be extended when these are initiated rapidly uptitrated during admission after discharge. A recent pilot study (CORTAHF) suggested benefits treating markers activation anti-inflammatory therapies. Future studies should further examine whether blockade lead reversal disrupted underlying remission AHF.
Language: Английский
Citations
1
European Journal of Heart Failure, Journal Year: 2024, Volume and Issue: 26(3), P. 638 - 651
Published: March 1, 2024
Language: Английский
Citations
6
European Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: 54(4)
Published: Jan. 18, 2024
DT reports personal fees from Alnylam Pharmaceuticals, Boehringer Ingelheim and Pfizer outside the submitted work. MA speaker Abbott Vascular Medtronic. MM consulting honoraria of minimal amount Abbott, Amgen, Bayer, Edwards Therapeutics, LivaNova Vifor Pharma for participation to advisory board meetings executive committees clinical trials. All other authors have no conflicts interest disclose.
Language: Английский
Citations
4
European Journal of Emergency Medicine, Journal Year: 2024, Volume and Issue: 31(4), P. 231 - 233
Published: June 25, 2024
aDepartment of Anesthesia-Reanimation, Cavale Blanche Hospital bLaboratoire ORPHY EA 4324, University Brest, France cClinic Cardiac and Vascular Diseases, Institute Clinical Medicine, Faculty Vilnius University, Vilnius, Lithuania dINSERM UMR-S 942 Paris eDepartment Lariboisière Hospital, Paris, Received 22 May 2024 Accepted 24 2024. Correspondence to Anais Caillard, MD, PhD, Department 29609 Boulevard Tanguy Prigent, 29200 Tel: +332 98 34 72 84; e-mail: [email protected]
Language: Английский
Citations
3
Circulation Heart Failure, Journal Year: 2024, Volume and Issue: 17(4)
Published: April 1, 2024
Language: Английский
Citations
2
Heart Failure Reviews, Journal Year: 2024, Volume and Issue: 29(5), P. 1065 - 1077
Published: July 22, 2024
Heart failure (HF) is a systemic disease associated with high risk of morbidity, mortality, increased hospitalizations, and low quality life. Therefore, effective, treatment strategies are necessary to mitigate these risks. In this manuscript, we emphasize the concept high-intensity care optimize guideline-directed medical therapy (GDMT) in HF patients. The document highlights importance achieving optimal recommended doses GDMT medications, including beta-blockers, renin-angiotensin-aldosterone inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter inhibitors improve patient outcomes, achieve sustainable decongestion, also discusses potential obstacles optimization, such as clinical inertia, physiological limitations, comorbidities, non-adherence, frailty. Lastly, it attempts provide possible future scenarios high-intensive that could outcomes.
Language: Английский
Citations
2
Advances in Therapy, Journal Year: 2024, Volume and Issue: 41(7), P. 2606 - 2634
Published: May 14, 2024
Over the course of 2023, numerous key clinical trials with valuable contributions to cardiology were published or presented at major international conferences. This review seeks summarise these and reflect on their context. The authors collated reviewed conferences during 2023 including American College Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), Society (ESC), Transcatheter Therapeutics (TCT), Heart (AHA), Rhythm (EHRA), Angiography (SCAI), TVT-The Summit (TVT) Research Technologies (CRT). Trials a broad relevance community those potential change current practice included. A total 80 identified inclusion. Key in acute coronary syndrome (ACS) antiplatelet management such as HOST-IDEA, T-PASS STOP-DAPT3 included addition several pivotal interventional ORBITA 2, MULTISTARS-AMI, ILUMIEN-IV, OCTIVUS OCTOBER. Additionally, evaluated new stent design technology BIOSTEMI, PARTHENOPE TRANSFORM. Structural intervention long-term data from PARTNER 3, durability transcatheter aortic valve (TAVI), regarding tricuspid TRISCEND II. failure (HF) prevention covered studies DAPA-MI, STEP-HF, ADVOR, DICTATE HF CAMEO-DAPA. In cardiac devices electrophysiology, trial exploring novel ablation strategies atrial fibrillation (AF) PULSED AF ADVENT further evaluating efficacy anticoagulation subclinical NOAH-AFNET 6, FRAIL AZALEA-TIMI 71. article presents summary past year should be interest both practising clinicians researchers.
Language: Английский
Citations
1
Orvosi Hetilap, Journal Year: 2024, Volume and Issue: 165(31), P. 1197 - 1205
Published: Aug. 4, 2024
Bevezetés: Az Európai Kardiológus Társaság 2023-ban megújított Szívelégtelenség Irányelve gyorsított terápiaoptimalizációt javasol minden, szívelégtelenségben szenvedő beteg számára hospitalizációt követően a prognózis javítása érdekében STRONG-HF vizsgálat alapján. Ugyanakkor szigorú randomizációs kritériumokkal rendelkezett, így napi gyakorlatban széles körű megvalósíthatóságáról nem állnak rendelkezésre adatok. Célkitűzés és módszer: Célkitűzésünk intézetünk Részlegén hospitalizált, majd Ambulanciánkon követett, kilenc, egymást követő terápiaoptimalizáción átesett, csökkent ejekciós frakciójú retrospektív pilotvizsgálatának bemutatása. A terápiaoptimalizációra való alkalmasságuk meghatározása alapján felállított kritériumok szerint történt (systolés vérnyomás ≥100 Hgmm, szívfrekvencia ≥60 min –1 , szérumkáliumszint ≤5 mmol/l, becsült glomerularis filtráció ≥30 ml/min/1,73 m 2 ). Eredmények: Vizsgált betegeink életkora 33 74 év közötti, felvételi NT-proBNP mediánértéke 4786 (1670–13283) pg/ml, filtrációs ráta 92 (58–101) 3,9 (3,6–4,3) systolés 134 (115–136) 113 (96–134) bal kamrai frakció 23 (20–34)% volt. kórházi felvételkor egy-egy betegnél céldózis alatti négyes hármas terápia került alkalmazásra, míg többi esetben stratégiai gyógyszerek közül kettő vagy kevesebb gyógyszercsoportot alkalmaztunk. Elbocsátáskor egy kivételével bevezetésre terápia: RASi (renin-angiotenzin-rendszer-gátló) esetén az elért dózis átlagosan 61%-a, βB (béta-blokkoló) 26%-a, MRA (mineralokortikoidreceptor-antagonista) 97%-a volt, SGLT2i- (nátrium-glükóz-kotranszporter-2-gátló) kezelésben nyolc részesült. hathetes utánkövetés során jelentős szövődmény jelentkezett. 94%-át, 93%-át, SGLT2i 100%-át értük el. Hat céldózisú feltitrálásra, három tünetes hypotonia és/vagy bradycardia gátolta dózisemelését. betegek visszajelzései terápiaoptimalizáció jelentett megterhelést, szoros kontroll azonban növelte biztonságérzetüket. Következtetés: Eseteink szívelégtelenség első vonalbeli gyógyszeres kezelésének nemzetközi irányelv szerinti terápiaoptimalizációja kivitelezhető biztonságos volt miatti követően. betegeken nagy dózisú elérhető. mind klinikustól, betegtől kellő odafigyelést igényelt. Orv Hetil. 2024; 165(31): 1197–1205.
Citations
1